A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Purpose:
To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor.
Patients and Methods:
This was a first-in-human, multicenter, open-label study in patients with advanced solid tumors harboring FGFR1–3 gene alterations. Eligible patients received oral Debio 1347 at escalating doses once daily until disease progression or intolerable toxicity. Dose-limiting toxicities (DLT) were evaluated during the first 4 weeks on treatment, pharmacokinetics/pharmacodynamics postfirst dose and after 4 weeks.
Results:
A total of 71 patients were screened and 58 treated with Debio 1347 at doses from 10 to 150 mg/day. Predominant tumor types were breast and biliary duct cancer, most common gene alterations were FGFR1 amplifications (40%) and mutations in FGFR2 (12%) and FGFR3 (17%); 12 patients (21%) showed FGFR fusions. Five patients at three dose levels had six DLTs (dry mouth/eyes, hyperamylasemia, hypercalcemia, hyperbilirubinemia, hyperphosphatemia, and stomatitis). The maximum tolerated dose was not reached, but dermatologic toxicity became sometimes dose limiting beyond the DLT period at ≥80 mg/day. Adverse events required dose modifications in 52% of patients, mostly due to dose-dependent, asymptomatic hyperphosphatemia (22%). RECIST responses were seen across tumor types and mechanisms of FGFR activation. Six patients, 3 with FGFR fusions, demonstrated partial responses, 10 additional patients' tumor size regressions of ≤30%. Plasma half-life was 11.5 hours. Serum phosphate increased with Debio 1347 plasma levels and confirmed target engagement at doses ≥60 mg/day.
Conclusions:
Preliminary efficacy was encouraging and tolerability acceptable up to 80 mg/day, which is now used in an extension part of the study.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Cancers
7 publications, 6.6%
|
|
|
Cancer Treatment Reviews
6 publications, 5.66%
|
|
|
Expert Opinion on Investigational Drugs
5 publications, 4.72%
|
|
|
Clinical Cancer Research
5 publications, 4.72%
|
|
|
Cells
4 publications, 3.77%
|
|
|
Frontiers in Oncology
4 publications, 3.77%
|
|
|
JCO Precision Oncology
4 publications, 3.77%
|
|
|
International Journal of Molecular Sciences
3 publications, 2.83%
|
|
|
Annals of Oncology
3 publications, 2.83%
|
|
|
Oncologist
3 publications, 2.83%
|
|
|
Therapeutic Advances in Medical Oncology
2 publications, 1.89%
|
|
|
Breast Cancer Research
2 publications, 1.89%
|
|
|
Nature Reviews Clinical Oncology
2 publications, 1.89%
|
|
|
Expert Opinion on Pharmacotherapy
2 publications, 1.89%
|
|
|
Cancer Science
2 publications, 1.89%
|
|
|
Endocrinology
1 publication, 0.94%
|
|
|
Future Oncology
1 publication, 0.94%
|
|
|
Aging
1 publication, 0.94%
|
|
|
Applied Immunohistochemistry and Molecular Morphology
1 publication, 0.94%
|
|
|
Cancer Control
1 publication, 0.94%
|
|
|
Biomolecules
1 publication, 0.94%
|
|
|
Diagnostics
1 publication, 0.94%
|
|
|
Medicina
1 publication, 0.94%
|
|
|
Pharmaceuticals
1 publication, 0.94%
|
|
|
Journal of Clinical Medicine
1 publication, 0.94%
|
|
|
Gastric Cancer
1 publication, 0.94%
|
|
|
Journal of Cancer Research and Clinical Oncology
1 publication, 0.94%
|
|
|
Nature
1 publication, 0.94%
|
|
|
Modern Pathology
1 publication, 0.94%
|
|
|
Journal of Biomolecular Structure and Dynamics
1 publication, 0.94%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
5
10
15
20
25
|
|
|
MDPI
21 publications, 19.81%
|
|
|
Elsevier
19 publications, 17.92%
|
|
|
Taylor & Francis
14 publications, 13.21%
|
|
|
Springer Nature
10 publications, 9.43%
|
|
|
Wiley
9 publications, 8.49%
|
|
|
American Association for Cancer Research (AACR)
7 publications, 6.6%
|
|
|
Frontiers Media S.A.
4 publications, 3.77%
|
|
|
American Society of Clinical Oncology (ASCO)
4 publications, 3.77%
|
|
|
Society for Translational Oncology
3 publications, 2.83%
|
|
|
SAGE
2 publications, 1.89%
|
|
|
The Endocrine Society
1 publication, 0.94%
|
|
|
Impact Journals
1 publication, 0.94%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.94%
|
|
|
Moffitt Cancer Center
1 publication, 0.94%
|
|
|
Oxford University Press
1 publication, 0.94%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.94%
|
|
|
SLACK
1 publication, 0.94%
|
|
|
Hans Publishers
1 publication, 0.94%
|
|
|
AME Publishing Company
1 publication, 0.94%
|
|
|
Bioscientifica
1 publication, 0.94%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.94%
|
|
|
Walter de Gruyter
1 publication, 0.94%
|
|
|
Jones and Barlett Publishers
1 publication, 0.94%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.